Navigation Links
TripleMaster PCR System

primer mix containing DMSO (see step 4 in protocol below and table 8). Protocol for GC-rich targets
  1. Thaw the reagents listed in Table 8 carefully and keep on ice.
  2. Make sure reagents are thoroughly thawed. Mix each reagent and briefly centrifuge before use.
  3. Set up Mastermix 1 (see Table 8) containing buffer, primer, template DNA and DMSO (optional) in a sterile microcentrifuge tube, mix well, centrifuge and heat for 30 seconds at 98C.
  4. Quickly spin down (2 sec) Mastermix 1 and immediately place on ice.
  5. Prepare Mastermix 2 (see Table 8) in a separate sterile microcentrifuge tube, mix well, centrifuge and place on ice.
  6. Just before cycling, pipette Mastermix 1 and then Mastermix 2 into a separate PCR tube on ice. Mix quickly but thoroughly, (vortex) and centrifuge.
  7. Place immediately into a thermal cycler that is pre-heated at 98C (use the "Hold" step for this) and start cycling.
  8. Analyze amplification products on a 0.6-1.5 % agarose gel using appropriate DNA markers.
Table 8: Mastermix conditions for GC-rich PCR 1 increase final buffer conc. (1.6x) for targets < 500 bp or when using a low concentration of template DNA per reaction (< 10 ng genomic DNA or < 0.5 ng plasmid DNA)
2 increase dNTP concentration for GC-rich targets

Table 9: Cycling program for GC-rich targets 1 Difficult targets require more cycles (and template DNA) for efficient amplificati
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. TripleMaster PCR System
2. The TripleMaster PCR System for three different amplifications
3. TripleMaster PCR System: Direct Comparison with Competitors
4. TripleMaster and Perfect gDNA Blood Mini Kit Team Up to Amplify Long gDNA Templates
5. TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR
6. Using the TripleMaster PCR System for Robust Amplification of GC-Rich DNA Templates
7. New Mammalian Two-Hybrid System Detects Protein-Protein Interactions
8. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
9. Generate Adenovirus Vectors in E. coli by Homologous Recombination with the AdEasy Adenoviral Vector System
10. New Yeast Cloning System for Producing Proteins with Native Amino Acid Sequences
11. Enhanced PCR Cloning System
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: TripleMaster PCR System

(Date:6/1/2015)... MONTREAL and YONGIN, South Korea ... with great pride that Green Cross Biotherapeutics Inc. (GCBT) ... will be located on the Montreal Technoparc,s Saint-Laurent Campus. ... green field investment projects in Canada ... construction of the first intravenous immunoglobulin (IVIG) and albumin ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
(Date:6/1/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") ... at the ERA-EDTA Congress in London, England ... a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in ... Disease (CKD); a Post-hoc Analysis of Patients from the ... Dr. Kam Kalantar-Zadeh , Professor and Chief, Division ...
Breaking Biology Technology:Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4
... Aug. 4 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), ... clinical trials announced today that the company has acquired the ... Ltd. The acquisition will be operated by OmniComm,s UK subsidiary, ... exceptional software is used to collect clinical trial data gathered ...
... molecule-sized pores are one step closer to replacing the ... of academic researchers is reporting. Writing this week ... membranes, ability to separate molecules in a mixture is ... processing (RTP). By heating the membranes from room temperature ...
... , , SAN FRANCISCO, Aug. ... positive drug sales/earnings and partnering and M&A deals. As a result, ... 6.5 percent, mirroring the Dow and Nasdaq, which closed the month ... for a July in years. , , Helping ...
Cached Biology Technology:OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 2Rapid heating prepares energy-saving zeolite for greater role in industrial separations 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 4Biotech Hot in July Driven by Positive Drug Data and Acquisitions 2Biotech Hot in July Driven by Positive Drug Data and Acquisitions 3Biotech Hot in July Driven by Positive Drug Data and Acquisitions 4Biotech Hot in July Driven by Positive Drug Data and Acquisitions 5
(Date:5/22/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... promotional pricing and making the Wocket generally available for $229 ... Head of Marketing said, "We,ve extended the opportunity to take ... May. To get your wocket at this special price, submit ... on June 1, you,ll receive a unique code that gives ...
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... at land-grant universities are a major source of ... industry. To prepare future employees for work in ... in nursery management and production, but availability of ... horticulture programs have contributed to a reduction in ...
... 2011 Dr. Daniel Von Hoff was presented this month ... in sequencing, or spelling out, the DNA of patients with ... advances the art of using the fully sequenced genomes of ... DNA, to help determine the best course of treatment. ...
... Mich. (March 17, 2011) In a ... so-called "orphan" nuclear receptor TR4, Van Andel Research Institute ... more direct role than was previously known in certain ... of the central nervous system. Scientists had previously ...
Cached Biology News:Integrating instructional multimedia in nursery management, production courses 2Dr. Daniel Von Hoff presented with top genomics award from Scripps 2Study indicates vitamin A plays key role in the human body 2
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Biology Products: